局部使用奈他舒地尔相关的泪点狭窄
本病例系列报告了16例使用0.02%奈他舒地尔滴眼液治疗青光眼后出现泪点狭窄的患者,其中13例单侧用药者出现单侧狭窄,3例双侧用药者出现双侧狭窄。从开始用药到发现症状或记录到泪点狭窄的时间为2至35个月(中位数12个月,均值14.0±8.7个月)。8例停药者泪点狭窄及伴随症状均逆转。
要点
- 使用0.02%奈他舒地尔滴眼液可能引起可逆的泪点狭窄。
- 16例患者中13例单侧用药出现单侧泪点狭窄,3例双侧用药出现双侧狭窄。
- 8例停药后泪点狭窄及伴随症状均逆转。
核心结论
- 使用奈他舒地尔可导致可逆性泪点狭窄,这种炎症介导的狭窄可能引起溢泪及相关症状,严重程度可能足以需要停用治疗。
研究设计与样本
- 病例系列;纳入使用局部奈他舒地尔治疗青光眼且用药同侧眼出现泪点狭窄的患者,复习病历并排查其他原因,部分患者拍照记录。
主要发现
- 16例患者出现泪点狭窄,其中13例单侧使用奈他舒地尔者出现单侧狭窄,3例双侧使用者出现双侧狭窄。
- 从开始使用奈他舒地尔到发现症状或记录到泪点狭窄的时间为2至35个月(中位数12个月,均值14.0±8.7个月)。
- 13例患者主诉溢泪,2例无症状;1眼可见睑外翻;14例(87.5%)可见角膜垂直纹。
- 8例停用奈他舒地尔后泪点狭窄逆转,相关症状缓解。
临床怎么用
- 作者在结论中指出,使用奈他舒地尔可能导致可逆性泪点狭窄,严重时可能需停用治疗;本病例系列中所有停药患者泪点狭窄及相关症状均逆转。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report a series of patients who developed punctal stenosis secondary to the use of topical netarsudil 0.02% for treatment of glaucoma. DESIGN: Case series. PARTICIPANTS: Patients using topical netarsudil for management of glaucoma and noted to have punctal stenosis ipsilateral to the eye(s) being treated with netarsudil were included. METHODS: Each enrolled patient's chart was reviewed, and alternative causes of punctal stenosis were sought. Photographs were obtained to document punctal stenosis for some patients. MAIN OUTCOME MEASURES: Presence of punctal stenosis after topical netarsudil use and resolution of punctal stenosis after cessation of therapy. RESULTS: Sixteen patients had punctal stenosis; 13 developed unilateral punctal stenosis while using netarsudil unilaterally, and 3 patients developed bilateral punctal stenosis with bilateral use. Time from initiation of netarsudil to recognition of symptoms or documentation of punctal stenosis ranged from 2 to 35 months (median, 12; mean, 14.0 ± 8.7 months). Thirteen patients endorsed tearing, but 2 had no symptoms. Ectropion was seen in 1 eye. Corneal verticillata was noted in 14 patients (87.5%). In 8 cases, netarsudil was discontinued, and the punctal stenosis was reversed, with resolution of associated symptoms. CONCLUSIONS: Netarsudil use can lead to the development of reversible punctal stenosis. This inflammation-mediated stenosis may cause tearing and associated symptoms and may be of sufficient severity to necessitate discontinuation of treatment. In this case series, all patients who discontinued treatment had reversal of their punctal stenosis and associated symptoms.
引用
- Meirick TM, Mudumbai RC, Zhang MM, et al. Punctal Stenosis Associated with Topical Netarsudil Use. Ophthalmology. 2022. PMID: 35231471. doi:10.1016/j.ophtha.2022.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。